Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,889 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06821490Enrolling by invitation
TAD biopsy for HER2+ breast cancer with positive lymph nodes
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Valencia, ValenciaAges 18 years+ - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT06826040RecruitingPhase 1
A study of SKB445 for solid tumors
This trial tests a new drug called SKB445 for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if the drug is safe and effective for these patients.
Jinan, ShandongAges 18–75 - NCT07208240RecruitingPhase 1/Phase 2
PSMA-targeted radiation before prostate removal for advanced cancer
This trial tests giving a radioactive drug (PSMA-targeted) before surgery for prostate cancer that has spread locally but not to other parts of the body. The goal is to see if it helps lower the risk of the cancer coming back.
Petah TikvaAges 18 years+ - NCT07204340RecruitingPhase 1
TLN-372 for advanced KRAS-mutant solid tumors
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
Birmingham, AlabamaAges 18 years+ - NCT06541639RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06866041Recruiting
Prostate cancer markers and imaging for low-risk patients on active surveillance
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
Milan, ItalyAges 45–80 - NCT06544577Recruiting
Elacestrant for advanced ER+/HER2- breast cancer with ESR1 mutation
This trial tests an oral drug called elacestrant in women whose ER+/HER2- breast cancer has worsened after at least one hormone therapy. It is for those with a specific genetic change (ESR1 mutation) and advanced or metastatic disease.
Qionghai, HainanAges 18 years+ - NCT05789043RecruitingPhase 3
Test of immunotherapy plus pills and chemotherapy for advanced melanoma
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
BeijingAges 18 years+ - NCT07263919RecruitingPhase 2
Chemo plus cadonilimab before surgery for esophageal cancer
This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.
Xi'anAges 18–75 - NCT07179757Recruiting
Vulvovaginal cancer treatment study
This study looks at how well treatments like radiation, chemotherapy, or surgery work for people with vulvar or vaginal cancer, and how they affect quality of life. It includes patients treated between 2019 and 2023.
Mumbai, MaharashtraAges Any age - NCT06549907Recruiting
Study of double immunotherapy plus anti-angiogenic therapy
This trial studies people with certain types of colorectal or other solid tumors that did not respond to a single immunotherapy drug. It tests whether adding a second immune checkpoint blocker and an anti-angiogenic drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06550687Recruiting
Studying how cancer patients like to learn about genetic results
This trial looks at the best ways to give cancer patients their genetic information before a special test called exome analysis. It aims to make sure you get the information in a way that feels right for you.
DijonAges 18 years+ - NCT06860477RecruitingPhase 2
Freezing therapy plus targeted drugs vs. chemotherapy for advanced bile duct cancer
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05749432RecruitingPhase 1
Testing a new medicine for advanced solid tumors
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
Beijing, Beijing MunicipalityAges 18–65 - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75 - NCT04656041RecruitingPhase 2
Test chemo with radiation for gastroesophageal cancer
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
Boston, MassachusettsAges 18 years+ - NCT07128914RecruitingPhase 1
Study of GO306 for advanced solid tumors
This trial tests a new drug called GO306 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have certain cancers like breast, bladder, colorectal, kidney, ovarian, or neuroendocrine tumors, and you have malignant ascites (fluid buildup in the belly) that needs treatment.
Hefei, AnhuiAges 18 years+ - NCT07644403Enrolling by invitationPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests IMC001, a new type of immune cell therapy designed to fight advanced solid cancers that have stopped responding to standard treatments. The therapy uses your own immune cells engineered to recognize and attack cancer cells.
BeijingAges 18–75 - NCT06594991RecruitingPhase 2
A study of three immunotherapy drugs for advanced melanoma
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06265688RecruitingPhase 1
First study of CX-2051 for advanced solid tumors
This study is testing a new drug called CX-2051 for people with advanced solid tumors that have not responded to standard treatments. The drug is a type of targeted therapy that delivers chemotherapy directly to cancer cells, and the goal is to see if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07100704RecruitingPhase 2
Nivolumab for recurrent olfactory neuroblastoma
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
Kashiwa, ChibaAges 18 years+ - NCT07231458RecruitingPhase 1
Testing a new immunotherapy with pembrolizumab for advanced solid tumors
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
BerlinAges 18 years+ - NCT07231081RecruitingPhase 1
TX103 CAR-T cells for advanced solid tumors
This trial tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have a specific protein (B7-H3). The goal is to see if these modified immune cells can shrink tumors or slow their growth.
BeijingAges 18–75
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,889 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.